Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Kidney and statins].

B Moulin1, S Caillard

  • 1Service de Néphrologie, Hôpitaux Universitaires de Strasbourg, Hôpital Civil, BP 426, 67091 Strasbourg. Bruno.Moulin@nephro.u-strasbg.fr

Annales D'Endocrinologie
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine release syndrome-associated encephalopathy in patients with COVID-19.

European journal of neurology·2020
Same author

Global Transplantation COVID Report March 2020.

Transplantation·2020
Same author

Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation.

The Journal of infection·2019
Same author

Type 1 primary hyperoxaluria: A case report and focus on bone impairment of systemic oxalosis.

Morphologie : bulletin de l'Association des anatomistes·2017
Same author

Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Intraoperative Pleth Variability Index Is Linked to Delayed Graft Function After Kidney Transplantation.

Transplantation proceedings·2016
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
Same journal

ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

Annales d'endocrinologie·2026
See all related articles

Statins are effective for managing lipid abnormalities in chronic renal disease (CRD) patients, reducing cardiovascular risks. Careful dosing and monitoring are essential, especially with renal failure or calcineurin inhibitors.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Context:

  • Patients with chronic renal diseases (CRD) exhibit a high prevalence of lipid abnormalities.
  • Elevated total and low-density lipoprotein (LDL) cholesterol levels are linked to cardiovascular diseases in CRD patients.

Purpose:

  • To evaluate the efficacy and safety of 3-hydroxy-methylglutaryl co-enzyme A reductase inhibitors (statins) in managing lipid disorders in CRD patients.
  • To explore the potential benefits of statins beyond LDL cholesterol reduction in atherosclerosis and CRD progression.

Summary:

  • Statins are the primary choice for lowering LDL cholesterol in CRD patients, generally safe with caution.
  • Dosage adjustments and close monitoring are necessary for renal failure patients or those on calcineurin inhibitors to prevent side effects.

Related Experiment Videos

  • Emerging evidence suggests statins may also impact atherosclerosis development and slow chronic renal failure progression.

    • Impact:

    • Statins can effectively manage dyslipidemia, a major risk factor for cardiovascular complications in CRD.
    • The findings support the expanded use of statins in renal patient management, potentially improving long-term outcomes.
    • Understanding statins' multifaceted effects can guide therapeutic strategies for patients with both kidney disease and cardiovascular risk.